Lupin Ltd — Capital/Financing Update 2019

Jul 3, 2019

==> picture [169 x 32] intentionally omitted <==

----- Start of picture text ----- Press Release----- End of picture text -----

==> picture [45 x 55] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN

Lupin receives U.S. FDA approval for Phenylephrine and Ketorolac Intraocular Solution

Mumbai, Baltimore, July 3, 2019: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%, from the United States Food and Drug Administration (U.S. FDA).

Lupin’s Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%, is the generic version of Omidria Intraocular Solution, 1%/0.3%, of Omeros Corporation (Omeros). It is indicated for:

• maintaining pupil size by preventing intraoperative miosis

• reducing postoperative ocular pain

• Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%, is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement.

Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%, had annual sales of approximately USD 42.8 million in the US (IQVIA MAT March 2019).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biosimilar products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8th largest generics pharmaceutical company by revenues (31st Dec 2018, Bloomberg LTM). The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT Mar 2019); 3rd largest Indian pharmaceutical company by global revenues (31st Dec 2018, Bloomberg LTM); 5th largest company in the Indian Pharmaceutical Market and 6th largest generic pharmaceutical player in Japan (IQVIA MAT Mar 2019).

For the financial year ended 31st March 2019, Lupin’s Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter at – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran VP – Corporate Communications Email: poojathakran@lupin.com Ph: +91-22-66402531 / 8291013225

Arvind Bothra Head – Investor Relations Email: arvindbothra@lupin.com Ph: +91-22-66408237

*Safe Harbor Statement Omidria® is a registered trademark of Omeros Corporation.